A treatment for post-COVID is being studied at the HUG
Seven months after infection with SARS-CoV-2, a third of patients still suffer from symptoms such as persistent fatigue, problems with their sense of smell, neurological or cardiac problems, shortness of breath, headaches and dizziness. Some of you, or people close to you, may be directly affected by these symptoms linked to post COVID (or long COVID).
A clinical trial being conducted by the Department of Primary Care Medicine at Geneva University Hospitals is evaluating the effectiveness of Temelimab, a treatment for the neurological symptoms of post-COVID, including memory loss, lack of concentration and fatigue.
People living in Switzerland, France, Belgium, Luxembourg or other countries are eligible to take part. Participation in the study is free and will take place over 6 months, with approximately one half-day visit per month to the HUG in Geneva. This clinical trial is independent of the studies conducted by the Population Epidemiology Unit.
Find out more about the trial in pictures
Find out more about participation criteria and joining the study
You can also contact the team in charge of the study directly:
Tel: +41 (0) 22 372 11 51
Download the participation brochure (168 kB)
